ResMed(RMD) - 2023 Q4 - Earnings Call Presentation

Unused borrowing capacity $745M $736.7 $351.1 $693.3 LTM 4Q21 LTM 4Q22 LTM 4Q23 Capital Expenditures ($M) Free Cash Flow ($M) $102.7 $134.8 $119.7 LTM 4Q21 LTM 4Q22 LTM 4Q23 $634.0 $216.3 $573.6 LTM 4Q21 LTM 4Q22 LTM 4Q23 Expect liquidity to improve as supply chain environment improves and inventory levels come down 9 © 2023 ResMed | Q4 2023 Earnings Presentation – Aug. 3, 2023 Track record of strong financial returns for shareholders (Financial data as of June 30, 2023) Revenue ($B) Non-GAAP Operating Inco ...